Christian O. Henry Sells 10,500 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock

Wave Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares in the company, valued at approximately $157,443.55. This trade represents a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Wave Life Sciences Price Performance

Wave Life Sciences stock traded down $0.63 during trading hours on Tuesday, hitting $9.44. The stock had a trading volume of 932,759 shares, compared to its average volume of 1,092,471. Wave Life Sciences Ltd. has a 1-year low of $4.25 and a 1-year high of $16.74. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.50 and a beta of -1.04. The stock's fifty day moving average is $10.89 and its two-hundred day moving average is $11.63.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.34. The firm had revenue of $83.75 million for the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. As a group, sell-side analysts anticipate that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its holdings in Wave Life Sciences by 209.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company's stock valued at $6,926,000 after buying an additional 571,345 shares during the last quarter. FMR LLC boosted its stake in shares of Wave Life Sciences by 174.5% during the third quarter. FMR LLC now owns 1,540,190 shares of the company's stock valued at $12,630,000 after acquiring an additional 979,110 shares during the last quarter. Maven Securities LTD purchased a new stake in Wave Life Sciences during the 3rd quarter worth about $6,970,000. Barclays PLC raised its stake in Wave Life Sciences by 171.1% in the 3rd quarter. Barclays PLC now owns 159,241 shares of the company's stock valued at $1,307,000 after purchasing an additional 100,498 shares during the last quarter. Finally, Cinctive Capital Management LP lifted its holdings in Wave Life Sciences by 255.7% in the 3rd quarter. Cinctive Capital Management LP now owns 356,308 shares of the company's stock valued at $2,922,000 after purchasing an additional 256,146 shares in the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on WVE shares. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday, March 5th. StockNews.com raised Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Jefferies Financial Group began coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Wave Life Sciences currently has an average rating of "Moderate Buy" and an average target price of $22.60.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.